Why should screening and testing for Alpha-1 antitrypsin deficiency (AATD) become common practice in your clinic?
AATD is a genetic hereditary condition that predisposes a person to the development of certain diseases (such as COPD).
Join our experts in this FREE 60-minute webinar as they discuss the results of our recent national survey, as well as the importance of AATD screening and testing and how you can make an impact on both the patient’s and family member’s journeys.
June 1, 2022
7-8 PM EST
- Understand the pathophysiology and genetics of AATD.
- Understand the consequences of AATD for individuals diagnosed with COPD.
- Review how to make a diagnosis of AATD.
- Discuss the role genetic counselling plays in an AATD for the patient and their family.
Registration closes in:
Alan Kaplan, MD, CCFP(EM), FCFP
Dr. Kaplan is a Family Physician working in York Region, Ontario, Canada and the Chairperson of the Family Physician Airways Group of Canada (www.fpagc.com), the Past-Chairperson of the Respiratory Section of the College of Family Physicians of Canada, and Senate member of the International Primary Care Respiratory Group. He co-chaired the Community Standards of COPD program for Health Quality Ontario. In addition, Dr. Kaplan provides his expertise to a number of medical journals across the world.
Nathalie Bolduc, MSc, CGC, CCGC
Nathalie Bolduc is currently the Director of Business Development at Genolife. Nathalie received her master’s degree in Genetic Counselling from McGill University and has over 25 years of experience in the public and private sector. She was President of Quebec Association of Genetic Counsellors and President of the Canadian Association of Genetic Counsellors. An excellent communicator and curious by nature, she works to demystify genetics through conferences to healthcare professionals and to the public. She is interested in advocating for the role of genetic counsellors in the integration of genomics into primary care.